178.4 USD
-0.69 (-0.39%)
Last: Feb 3, 2026, 10:55 AM
BIIB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. BIIB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BIIB is valued quite cheap, but it does not seem to be growing. These ratings would make BIIB suitable for value investing!
1. Profitability
1.1 Basic Checks
- BIIB had positive earnings in the past year.
- In the past year BIIB had a positive cash flow from operations.
- Each year in the past 5 years BIIB has been profitable.
- BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BIIB's Return On Assets of 5.51% is amongst the best of the industry. BIIB outperforms 92.18% of its industry peers.
- The Return On Equity of BIIB (8.84%) is better than 92.37% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 9.70%, BIIB belongs to the top of the industry, outperforming 94.66% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 18.09%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
- Looking at the Profit Margin, with a value of 15.98%, BIIB belongs to the top of the industry, outperforming 92.56% of the companies in the same industry.
- BIIB's Profit Margin has declined in the last couple of years.
- The Operating Margin of BIIB (28.50%) is better than 96.76% of its industry peers.
- In the last couple of years the Operating Margin of BIIB has declined.
- Looking at the Gross Margin, with a value of 75.24%, BIIB belongs to the top of the industry, outperforming 83.78% of the companies in the same industry.
- BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
- BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- BIIB has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BIIB has been reduced compared to 5 years ago.
- Compared to 1 year ago, BIIB has an improved debt to assets ratio.
2.2 Solvency
- BIIB has an Altman-Z score of 3.32. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
- BIIB's Altman-Z score of 3.32 is fine compared to the rest of the industry. BIIB outperforms 69.47% of its industry peers.
- BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as BIIB would need 2.78 years to pay back of all of its debts.
- The Debt to FCF ratio of BIIB (2.78) is better than 92.94% of its industry peers.
- BIIB has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
- BIIB's Debt to Equity ratio of 0.35 is on the low side compared to the rest of the industry. BIIB is outperformed by 68.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.32 |
ROIC/WACC1.15
WACC8.4%
2.3 Liquidity
- A Current Ratio of 2.72 indicates that BIIB has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 2.72, BIIB is doing worse than 68.32% of the companies in the same industry.
- BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.04, BIIB is not doing good in the industry: 73.47% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 2.51% over the past year.
- The earnings per share for BIIB have been decreasing by -13.31% on average. This is quite bad
- The Revenue has been growing slightly by 4.77% in the past year.
- BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
- The Earnings Per Share is expected to grow by 0.59% on average over the next years.
- BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.36%
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
EPS Next 5Y0.59%
Revenue Next Year1.98%
Revenue Next 2Y-1.62%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 10.66, which indicates a very decent valuation of BIIB.
- Based on the Price/Earnings ratio, BIIB is valued cheaper than 97.90% of the companies in the same industry.
- When comparing the Price/Earnings ratio of BIIB to the average of the S&P500 Index (28.41), we can say BIIB is valued rather cheaply.
- BIIB is valuated reasonably with a Price/Forward Earnings ratio of 11.55.
- Based on the Price/Forward Earnings ratio, BIIB is valued cheaper than 98.09% of the companies in the same industry.
- BIIB is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.64, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.66 | ||
| Fwd PE | 11.55 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaper than 98.47% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 98.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.57 | ||
| EV/EBITDA | 7.85 |
4.3 Compensation for Growth
- The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
5. Dividend
5.1 Amount
- No dividends for BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BIIB (2/3/2026, 10:55:04 AM)
178.4
-0.69 (-0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-06 2026-02-06/bmo
Inst Owners96.04%
Inst Owner Change-1.64%
Ins Owners0.15%
Ins Owner Change0.74%
Market Cap26.17B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target193.25 (8.32%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)5.38%
PT rev (3m)10.41%
EPS NQ rev (1m)2.53%
EPS NQ rev (3m)-52.97%
EPS NY rev (1m)0.19%
EPS NY rev (3m)-5.23%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)-2.6%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.66 | ||
| Fwd PE | 11.55 | ||
| P/S | 2.6 | ||
| P/FCF | 11.57 | ||
| P/OCF | 10.67 | ||
| P/B | 1.44 | ||
| P/tB | 10.97 | ||
| EV/EBITDA | 7.85 |
EPS(TTM)16.74
EY9.38%
EPS(NY)15.45
Fwd EY8.66%
FCF(TTM)15.42
FCFY8.64%
OCF(TTM)16.73
OCFY9.38%
SpS68.62
BVpS124.11
TBVpS16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.32 |
F-Score5
WACC8.4%
ROIC/WACC1.15
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.36%
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.98%
Revenue Next 2Y-1.62%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status of BIOGEN INC (BIIB) stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
How financially healthy is BIOGEN INC?
The financial health rating of BIOGEN INC (BIIB) is 7 / 10.